Literature DB >> 15026261

Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection.

Susan C Fagan1, David J Edwards, Cesar V Borlongan, Lin Xu, Ankur Arora, Giora Feuerstein, David C Hess.   

Abstract

Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15026261     DOI： 10.1016/j.expneurol.2003.12.006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


  47 in total

1.  Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial.

Authors:  Carolyn I Rodriguez; James Bender; Sue M Marcus; Michael Snape; Moira Rynn; Helen Blair Simpson
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

3.  Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice.

Authors:  Hu Chen; Hari Manev
Journal:  Neuropharmacology       Date:  2010-09-22       Impact factor: 5.250

Review 4.  Tetracyclines and pain.

Authors:  Leandro F S Bastos; Antônio C P de Oliveira; Linda R Watkins; Márcio F D Moraes; Márcio M Coelho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-27       Impact factor: 3.000

5.  Comparison of the effect of minocycline and simvastatin on functional recovery and gene expression in a rat traumatic brain injury model.

Authors:  Cole Vonder Haar; Gail D Anderson; Brandy E Elmore; Lynn H Moore; Amanda M Wright; Eric D Kantor; Fred M Farin; Theo K Bammler; James W MacDonald; Michael R Hoane
Journal:  J Neurotrauma       Date:  2014-01-20       Impact factor: 5.269

6.  Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy.

Authors:  Ping Yan; Alec Zhu; Fan Liao; Qingli Xiao; Andrew Kraft; Ernie Gonzales; Ron Perez; Steven M Greenberg; David Holtzman; Jin-Moo Lee
Journal:  Stroke       Date:  2015-05-05       Impact factor: 7.914

7.  A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice.

Authors:  L F S Bastos; A Angusti; M C Vilaça; L A Merlo; E B Nascimento; L T S Rocha; A M Godin; A G R Solano; S Jarussophon; E A Nunan; Y Konishi; M M Coelho
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

8.  Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors.

Authors:  Marta Imbesi; Tolga Uz; Radmila Manev; Rajiv P Sharma; Hari Manev
Journal:  Neurosci Lett       Date:  2008-10-07       Impact factor: 3.046

9.  Minocycline inhibits glial proliferation in the H-Tx rat model of congenital hydrocephalus.

Authors:  James P McAllister; Janet M Miller
Journal:  Cerebrospinal Fluid Res       Date:  2010-05-27

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.